Both Detection, False-Positives Up With Digital Mammograms

Share this content:
Both Detection, False-Positives Up With Digital Mammograms
Both Detection, False-Positives Up With Digital Mammograms

TUESDAY, Feb. 28, 2017 (HealthDay News) -- Digital imaging has improved diagnostic capability of mammograms but the percentage of false-positives is up, too, according to a study published online Feb. 28 in Radiology.

Brian Sprague, Ph.D., associate professor of surgery at the University of Vermont College of Medicine in Burlington, and colleagues used information from six registries maintained by the Breast Cancer Surveillance Consortium, which is funded by the U.S. National Cancer Institute. The investigators evaluated results of 401,548 mammograms, reviewing data from 418 radiologists and 92 radiology facilities. The exams were conducted on 265,360 women.

The investigators found that 27.5 percent of the women who had a biopsy actually had cancer, compared to 31.5 percent in 2005. The breast cancer detection rate rose to 34.7 per 1,000 diagnostic mammograms from 2007 to 2013. That's up from 25.3 per 1,000 noted in a 2005 report from the Breast Cancer Surveillance Consortium. The rate at which women were called back for a biopsy rose to 12.6 percent, up from 8.0 percent in the earlier report.

"Compared with performance during the screen-film mammography era, diagnostic digital performance showed increased abnormal interpretation and cancer detection rates and decreasing positive predictive values (PPVs), with less than 70 percent of radiologists within acceptable ranges for PPV2 and PPV3," the authors write.

Two authors disclosed financial ties to G.E. Healthcare.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »